Remove Bioinformatics Remove Protein Expression Remove Therapies
article thumbnail

ADCs: the next generation of targeted therapies 

Drug Discovery World

Getting new targets for ADCs is a high priority as it could lead to therapies that are more likely to hit cancer cells, allowing for higher doses and greater efficacy with fewer trade-offs needed to ensure an acceptable safety profile.

Therapies 162
article thumbnail

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Debets will present: ‘Selection and validation of TCR-like antibodies and TCRs for adoptive therapy’. from engineered peptide and antibody libraries’.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Reflecting on PEGS Europe 2023 

Drug Discovery World

This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It CAR T cell therapies and in vivo solutions Thomas attended a presentation by Chad May, CSO of Serotiny, called: ‘Improving cell therapies with high-throughput CAR libraries’, in the session relating to optimising CARs.

article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

These include: Samantha Bailey-Bucktrout, PhD, Senior Vice President, Akamis Bio, on: ‘Tumour specific immunogene therapy to deliver protein therapeutics to solid tumour microenvironments’. Chairperson Klampatsa on: ‘Overcoming tumour antigen heterogeneity in the context of car t cell therapy for solid tumours’.

article thumbnail

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

Novel/alternative ML-enabled screening technologies for higher POS Following chairperson’s remarks from M Frank Erasmus, PhD, Head, Bioinformatics, Specifica, there will be four presentations and a panel discussion. Jürgen Kuball, PhD, Head, Hematology, University Medical Center Utrecht, on: ‘gdT cell inspired therapies’.